tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neurocrine price target raised to $149 from $144 at RBC Capital

RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $149 from $144 and keeps an Outperform rating on the shares. The firm’s analysis of the latest prescription trends suggests that Crenessity’s strong launch is likely to continue and that the drug should beat Q3 consensus expectations, the analyst tells investors in a research note. Shares look to have appreciated closer to fair value, perhaps reflecting increasing near-term optimism, RBC added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1